Ping Li1, Quanyong He1, Chenqun Luo1, Liyuan Qian2. 1. Department of Cosmetic Surgery, The Third Xiangya Hospital, Central South University Changsha, Hunan, China. 2. Department of General Surgery, The Third Xiangya Hospital, Central South University Changsha, Hunan, China.
Abstract
BACKGROUND: Accumulating evidence demonstrated a link of increased expression of Angiopoietin-2 (Ang-2) with invasive and metastatic phenotypes of various types of human cancers. However, until now, the serum level and its diagnostic and prognostic potential in breast cancer have not been investigated. METHODS: Enzyme-linked immunosorbent assays were used to measure the levels of Ang-2. Sensitivity, specificity and area under curve (AUC) for serum Ang-2 levels were determined using receiver operator characteristic (ROC) analysis. Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test. Prognostic relevance of each variable to overall survival (OS) and disease-free survival (DFS) were analyzed using the Cox regression model. RESULTS: Serum expression of Ang-2 in patients with breast cancer was significantly higher than healthy control group (3171 ± 1024 vs. 1800 ± 874 pg/ml, P < 0.0001). ROC curve analysis showed that at the optimal cut-off (2558.5 pg/ml), serum level of Ang-2 had a sensitivity of 78.3% and a specificity of 77.0% for distinguishing breast cancer patients from healthy controls with an area under the curve (AUC) of 0.836 (P < 0.001, 95% confidence interval: 0.787-0.885). The 5-year OS of high Ang-2 expression group was significantly shorter than that of low Ang-2 expression group (55.9% vs. 80.3%; P = 0.018). Moreover, the 5-year DFS of high Ang-2 expression group was also significantly shorter than that of low Ang-2 expression group (46.0% vs. 68.7%; P = 0.029). CONCLUSIONS: Our data indicate that serum Ang-2 level has potential value for early detection of breast cancer. Furthermore, Ang-2 has prognostic value in patients with breast cancer.
BACKGROUND: Accumulating evidence demonstrated a link of increased expression of Angiopoietin-2 (Ang-2) with invasive and metastatic phenotypes of various types of humancancers. However, until now, the serum level and its diagnostic and prognostic potential in breast cancer have not been investigated. METHODS: Enzyme-linked immunosorbent assays were used to measure the levels of Ang-2. Sensitivity, specificity and area under curve (AUC) for serum Ang-2 levels were determined using receiver operator characteristic (ROC) analysis. Survival curves were plotted using the Kaplan-Meier method and differences in survival rates were analyzed using the log-rank test. Prognostic relevance of each variable to overall survival (OS) and disease-free survival (DFS) were analyzed using the Cox regression model. RESULTS: Serum expression of Ang-2 in patients with breast cancer was significantly higher than healthy control group (3171 ± 1024 vs. 1800 ± 874 pg/ml, P < 0.0001). ROC curve analysis showed that at the optimal cut-off (2558.5 pg/ml), serum level of Ang-2 had a sensitivity of 78.3% and a specificity of 77.0% for distinguishing breast cancerpatients from healthy controls with an area under the curve (AUC) of 0.836 (P < 0.001, 95% confidence interval: 0.787-0.885). The 5-year OS of high Ang-2 expression group was significantly shorter than that of low Ang-2 expression group (55.9% vs. 80.3%; P = 0.018). Moreover, the 5-year DFS of high Ang-2 expression group was also significantly shorter than that of low Ang-2 expression group (46.0% vs. 68.7%; P = 0.029). CONCLUSIONS: Our data indicate that serum Ang-2 level has potential value for early detection of breast cancer. Furthermore, Ang-2 has prognostic value in patients with breast cancer.
Entities:
Keywords:
Angiopoietin-2; breast cancer; diagnosis; prognosis
Authors: Constantina A Pappa; George Tsirakis; Panagiotis Samiotakis; Maria Tsigaridaki; Athanasios Alegakis; Nectaria Goulidaki; Michael G Alexandrakis Journal: Cancer Invest Date: 2013-06-11 Impact factor: 2.176
Authors: Jiha Kim; Pedro Correa de Sampaio; Donna Marie Lundy; Qian Peng; Kurt W Evans; Hikaru Sugimoto; Mihai Gagea; Yvonne Kienast; Nayra Soares do Amaral; Rafael Malagoli Rocha; Hans Petter Eikesdal; Per Eystein Lønning; Funda Meric-Bernstam; Valerie S LeBleu Journal: JCI Insight Date: 2016-12-22
Authors: Florence T H Wu; Shan Man; Ping Xu; Annabelle Chow; Marta Paez-Ribes; Christina R Lee; Steven R Pirie-Shepherd; Urban Emmenegger; Robert S Kerbel Journal: Cancer Res Date: 2016-09-20 Impact factor: 12.701
Authors: Italia Grenga; Anna R Kwilas; Renee N Donahue; Benedetto Farsaci; James W Hodge Journal: J Immunother Cancer Date: 2015-11-17 Impact factor: 13.751
Authors: Vishwajith Sridharan; Danielle N Margalit; Stephanie A Lynch; Mariano Severgnini; F Stephen Hodi; Robert I Haddad; Roy B Tishler; Jonathan D Schoenfeld Journal: J Immunother Cancer Date: 2016-06-21 Impact factor: 13.751